Updates are available Correction dated 2025-12-18
Click to view Correction: https://doi.org/10.1007/s10238-025-01988-2
-
Authors
Cecere, Fabiana Letizia
D’Argento, Ettore https://orcid.org/0000-0001-8802-9876
Gelsomino, Francesco https://orcid.org/0000-0002-9204-1728
Pesola, Francesco https://orcid.org/0000-0001-7735-8973
Bironzo, Paolo https://orcid.org/0000-0002-2784-5076
Grisanti, Salvatore https://orcid.org/0000-0001-6922-1934
Bonanno, Laura https://orcid.org/0000-0001-5218-4970
Spitaleri, Gianluca https://orcid.org/0000-0003-3742-9962
Valsecchi, Diletta https://orcid.org/0009-0009-3268-0876
Marcon, Ilaria https://orcid.org/0009-0001-1363-899X
Cortinovis, Diego https://orcid.org/0000-0001-7611-7369
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 3 October 2025
First Online: 18 November 2025
Change Date: 18 December 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10238-025-01988-2
Declarations
:
: Fabiana Cecere declares no conflicts of interest. Ettore D’Argento declares no conflicts of interest. Francesco Gelsomino has received honoraria for advisory roles or consulting from Eli Lilly, Novartis, AstraZeneca, Regeneron, Pfizer, and BMS outside of this work. Francesco Pesola has received honoraria for advisory roles or consulting from Novartis and Italfarmaco. Paolo Bironzo has received honoraria for advisory roles or consulting from AstraZeneca, Diaceutics, Johnson and Johnson, Pierre-Fabre, Regeneron, and Seagen outside of this work. He received institutional research grants from Pfizer and Roche. Salvatore Grisanti received fees for advisory boards from the following companies: AstraZeneca, BMS, MSD, Novartis, Pfizer, Regeneron, Roche, and Takeda. Laura Bonanno received speaker fees or honoraria for advisory boards from AstraZeneca, MSD, BMS, Roche, Pfizer, Novartis, Takeda, and Lilly; research support from AstraZeneca; served as coordinating PI and participated in a steering committee for AstraZeneca. Gianluca Spitaleri received honoraria for advisory boards from Takeda. Diletta Valsecchi is an employee at Novartis Farma spa. Ilaria Marcon is an employee at Novartis Farma spa. Diego Cortinovis has acted as a consultant or advisor to Roche, AstraZeneca, BMS, MSD, Boehringer Ingelheim, Amgen, Novartis, Lilly, Seagen, Takeda, GSK, BeiGene, Pfizer, and J&J/Thermo Fisher Scientific.
: The treating physicians obtained written informed consent, related to the treatment in compassionate use and the processing and use of data, from all participants or their representatives prior to the start of treatment, in accordance with local laws and regulations and in line with the ethical principles outlined in the Declaration of Helsinki. As per the local laws and regulations (DECREE 17A07305 [ GU Serie Generale n.256 del 02–11-2017 ]), ethics approval was not required for this retrospective analysis.
